Lukas Biomedical

Lukas Biomedical Current Liabilities

The Current Liabilities of Lukas Biomedical (6814.TWO) as of Oct 27, 2026 is 4.17 M TWD. In the previous year, Current Liabilities was 81.89 M TWD — a change of -94.91% (lower).

Current Liabilities

4.17 MTWD

YoY

-94.91%

Last updated:

Current Liabilities of Lukas Biomedical is 2025 4.17 M TWD. Current Liabilities of Lukas Biomedical was 2024 81.89 M TWD. It decreases by -94.91% lower compared to the previous year.

The Lukas Biomedical Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
74.72 M TWD
Jan 1, 2019
114.22 M TWD
Jan 1, 2020
109.30 M TWD
Jan 1, 2021
134.79 M TWD
Jan 1, 2022
47.04 M TWD
Jan 1, 2023
101.78 M TWD
Jan 1, 2024
81.89 M TWD
Jan 1, 2025
4.17 M TWD
The Lukas Biomedical Current Liabilities history
YEARCurrent LiabilitiesYoY
4.17 MTWD-94.91%
81.89 MTWD-19.54%
101.78 MTWD+116.37%
47.04 MTWD-65.10%
134.79 MTWD+23.32%
109.30 MTWD-4.31%
114.22 MTWD+52.86%
74.72 MTWD-13.66%
86.55 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lukas Biomedical Stock analysis

What does Lukas Biomedical do? Lukas Biomedical, Inc. generates revenue through the lease and sale of medical equipment, as well as the research, design, development, and manufacture of immune cell products. The company offers beauty cosmetics, skin care products, and daily necessities such as dental floss, chewing gum, chewing spray, and dry hair products. Its makeup series includes eye shadow gel, eye color palette, lip gloss, lipstick, and lip wax. The firm provides services like brand authorization, management consulting, property leasing, and medical equipment leasing under an experience charging model for care institutions and medical management. The company’s products target consumers in the beauty and healthcare sectors, with medical equipment leased to care institutions and medical management entities. Immune cell products are developed for medical applications, while beauty and daily necessity products cater to personal care markets. The firm’s service model combines brand authorization with property and equipment leasing to support operational experience in healthcare facilities. Lukas Biomedical’s revenue streams include direct sales of medical equipment, lease agreements for medical devices, and the sale of immune cell products, beauty cosmetics, and daily necessities. Care institutions and medical management companies are key clients for leasing services, while beauty product lines serve individual consumers and retail channels. The experience charging model integrates brand authorization and management consulting to enhance service offerings for healthcare providers. Lukas Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lukas Biomedical stock

Current Liabilities of Lukas Biomedical is 4.17 M TWD in 2025.

Current Liabilities of Lukas Biomedical changed from 81.89 M TWD to 4.17 M TWD, representing a -94.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Lukas Biomedical since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Lukas Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lukas Biomedical

All Key Metrics — Lukas Biomedical